Skip to main content
SpringerLink
Log in

Cyclooxygenase-2 inhibitor treatment of older osteoarthritis patients

  • Original Article
  • Published:
Comprehensive Therapy

Abstract

Nonsteroidal anti-inflammatory drugs are often prescribed to treat osteoarthritis. Two cyclooxygenase isoenzymes prompted the development selective COX-2 inhibitors. The development, efficacy, and toxicity of COX-2 inhibitor treatment of osteoarthritis are summarized.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rofecoxib (Bioxx) prescribing information. Merck & Co. Whitehouse Station, NJ; 1998. Revised April, 2002.

  2. Celecoxib (Celebrex) prescribing information. G.D. Searle & Co.; 1998.

  3. Valdecoxib (Bextra) prescribing information; Pharmacia Corp./Pfizer Inc; 2001.

  4. Felson DT, Zhang Y, Hannan MT, et al. The incidence and natural history of knee osteoarthritis in the elderly. The Framingham Osteoarthritis Study. Arthritis Rheum. 1995;38: 1500–5.

    Article  PubMed  CAS  Google Scholar 

  5. Guccione A, Felson D, Anderson J, et al. The effects of specific medical conditions on the functional limitations of elders in the Framingham Study. Am J Public Health. 1994; 84:351–8.

    PubMed  CAS  Google Scholar 

  6. Guccione A, Felson D, Anderson J, et al. Defining arthritis and measuring functional status in elders: Methodological issues in the study of disease and physical disability. Am J Public Health. 1990;80:945–9.

    PubMed  CAS  Google Scholar 

  7. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 1999;340:1888–99.

    Article  PubMed  CAS  Google Scholar 

  8. Griffin M, Piper J, Daugherty J, et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med. 1991;114: 257–263.

    PubMed  CAS  Google Scholar 

  9. Cheatum D, Arvanitakis C, Gumpel M, et al. An endoscopic study of gastroduodenal lesions induced by nonsteroidal anti-inflammatory drugs. Clin Ther. 1999;21:992–1003.

    Article  PubMed  CAS  Google Scholar 

  10. Lichtenstein D, Syngal S, Wolfe M. Nonsteroidal anti-inflammatory drugs and the gastrointestinal tract. Arthritis Rheum. 1995;38:5–18.

    Article  PubMed  CAS  Google Scholar 

  11. Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol. 1999; 26:18–24.

    Google Scholar 

  12. Rahme E, Joseph L, Kong S, et al. Gastrointestinal health care resource use and costs associated with nonsteroidal anti-inflammatory drugs versus acetaminophen. Arthritis Rheum. 2000;43:917–924.

    Article  PubMed  CAS  Google Scholar 

  13. Johnson R, Hornbrook M, Hooker R, et al. Analysis of the costs of NSAID-associated gastropathy. Experience in a US health maintenance organization. Pharmacoeconomics. 1997; 12:76–88.

    PubMed  CAS  Google Scholar 

  14. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: Physiologic foundations and clinical implications. Am J Med. 1999;106:13S-24S.

    Article  PubMed  CAS  Google Scholar 

  15. Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients. Arch Intern Med. 2000;160:777–784.

    Article  PubMed  CAS  Google Scholar 

  16. Schafer AI. Effects of nonsteroidal anti-inflammatory therapy on platelets. Am J Med. 1999;106:25S-36S.

    Article  PubMed  CAS  Google Scholar 

  17. Vane J. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biology. 1971;231:232–235.

    PubMed  CAS  Google Scholar 

  18. Ferreira S, Moncada S, Vane J. Indomethacin and aspirin abolish prostaglandin release from the spleen. Nature New Biology. 1971;231:237–239.

    Article  PubMed  CAS  Google Scholar 

  19. Smith J, Willis A. Aspirin selectively inhibits prostaglandin production in human platelets. Nature New Biology. 1971; 231:235–237.

    Article  PubMed  CAS  Google Scholar 

  20. Picot D, Loll P, Garavito R. The x-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature. 1994;367:243–249.

    Article  PubMed  CAS  Google Scholar 

  21. Sirois J, Richards J. Purification and characterisation of a novel, distinct isoform of prostaglandin endoperoxide synthase induced by human chorionic gonadotropin in granulosa cells of rat preovulatory follicles. J Biol Chem. 1992; 267:6382–6388.

    PubMed  CAS  Google Scholar 

  22. Luong C, Miller A, Barnett J, et al. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nat Struct Biol. 1996;3:927–933.

    Article  PubMed  CAS  Google Scholar 

  23. Kraemer S, Meade S, DeWitt D. Prostaglandin endoperoxide synthase gene structure: Identification of the transcriptional start site and 5′-flanking regulatory sequences. Arch Biochem Biophys. 1992;293:391–400.

    Article  PubMed  CAS  Google Scholar 

  24. Fletcher B, Kujubu D, Perrin D, et al. Structure of the mitogen-inducible TIS10 gene and functional prostaglandin G/H synthase. J Biol Chem. 1992;267:4338–4344.

    PubMed  CAS  Google Scholar 

  25. Crofford L. COX-1 and COX-2 tissue expression: Implications and predictions. J Rheumatol. 1997;24:15–19.

    Google Scholar 

  26. Rossat J, Maillard M, Nussberger J, et al. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther. 1999;66:76–84.

    Article  PubMed  CAS  Google Scholar 

  27. Chan C. Rofecoxib (Vioxx, MK-0966; 4-4′-methylsulfonylphenyl-3-phenyl-2-5H-furanone): A potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther. 1999;290:551–560.

    PubMed  CAS  Google Scholar 

  28. Ehrich E, Ballob A, De Lepeleire I, et al. Characterisation of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther. 1999;65:336–347.

    Article  PubMed  CAS  Google Scholar 

  29. Ehrich E, Schnitzer T, Kivitz A, et al. MK-0966, a highly selective COX-2 inhibitor, was effective in the treatment of osteoarthritis of the knee and hip in a 6-week placebo controlled study [Abstract]. Arthritis Rheum. 1997;40:S85.

    Google Scholar 

  30. Simon L, Lanza F, Lipsky P, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor. Arthritis Rheum. 1998;41:1591–1602.

    Article  PubMed  CAS  Google Scholar 

  31. Day R, Morrison B, Luza A, et al. A Randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Arch Intern Med. 2000;160:1781–1787.

    Article  PubMed  CAS  Google Scholar 

  32. Cannon G, Caldwell J, Holt P, et al. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium. Arthritis Rheum. 2000; 43:978–987.

    Article  PubMed  CAS  Google Scholar 

  33. Saag K, Fisher C, McKay J, et al. MK-0966, A specific COX-2 inhibitor has clinical efficacy comparable to ibuprofen in the treatment of knee and hip osteoarthritis in a 6-week controlled clinical trial [Abstract]. Arthritis Rheum. 1998; 41:S196.

    Google Scholar 

  34. Bensen W, Fiechtner J, McMillen J, Zhao W, et al. Treatment of Osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: A randomized controlled trial. Mayo Clin Proc. 1999;74:1095–1105.

    PubMed  CAS  Google Scholar 

  35. Geba G, Polis A, Dixon M, et al. Rofecoxib results in superior clinical response compared to nabumetone in the treatment of osteoarthritis [Abstract]. Arthritis Rheum. 1999; 42:S144.

    Google Scholar 

  36. Kivitz AJ, Moskowitz RW, Woods E, et al. Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hip. J Intern Med Res. 2001;29: 467–479.

    CAS  Google Scholar 

  37. McKenna F, Borenstein D, Wendt H, et al. Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scand J Rheum. 2001;30:11–18.

    Article  PubMed  CAS  Google Scholar 

  38. Williams GW, Hubbard RC, Yu SS, et al. Comparison of once-daily and twice-daily administration of celecoxib for the treatment of osteoarthritis of the knee. Clin Ther. 2001; 23:213–227.

    Article  PubMed  CAS  Google Scholar 

  39. Kivitz A, Eisen G, Zhao WW, et al. Randomized placebo controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis. J Family Prac. 2002;51:530–537.

    Google Scholar 

  40. Makarowski W, Zhao WW, Bevirt T, et al. Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: A randomized, double-blind, placebo-controlled comparison with naproxen. Osteoarthritis Cartilage. 2002;10:290–296.

    Article  PubMed  CAS  Google Scholar 

  41. Geba GP, Weaver AL, Polis AB, et al. Efficacy of rofecoxib, celecoxib and acetaminophen in osteoarthritis of the knee A randomized trial. JAMA. 2002;287:64–71.

    Article  PubMed  CAS  Google Scholar 

  42. McKenna F, Weaver A, Fiechtner JJ, et al. COX-2 specific inhibitors in the management of osteoarthritis of the knee: A placebo-controlled randomized, double-blind study. J Clin Rheum. 2001;7:151–159.

    Article  CAS  Google Scholar 

  43. Lanza F, Rack M, Simon T, et al. Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen. Aliment Pharmacol Ther. 1999;13:761–767.

    Article  PubMed  CAS  Google Scholar 

  44. Hawkey C, Laine L, Simon T, et al. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen and placebo on the gastroduodenal mucosa of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational study group. Arthritis Rheum. 2000;43:370–377.

    Article  PubMed  CAS  Google Scholar 

  45. Langman M, Jensen D, Watson D, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA. 1999;282:1961–1963.

    Article  Google Scholar 

  46. Watson DJ, Harper SE, Zhao P, et al. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Arch Intern Med. 2000;160: 2998–3003.

    Article  PubMed  CAS  Google Scholar 

  47. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343: 1520–1528.

    Article  PubMed  CAS  Google Scholar 

  48. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: A randomized controlled trial. JAMA. 2000; 284:1247–1255.

    Article  PubMed  CAS  Google Scholar 

  49. Schoenfeld P. An evidence-based approach to the gastrointestinal safety profile of COX-2 selective anti-inflammatories. Gastroenterol Clin North Am. 2001;30:1027–1044.

    Article  PubMed  CAS  Google Scholar 

  50. Goldstein JL, Silverstein FE, Agrawal NM, et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib: novel COX-2 inhibitor. Am J Gastroenterol 2000;95: 1681–1690.

    Article  PubMed  CAS  Google Scholar 

  51. Goldstein JL, Correa P, Zhao, ww, et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol. 2001;96:1019–1027.

    Article  PubMed  CAS  Google Scholar 

  52. Bensen, WG, Zhao SZ, Burke TA, et al. Upper gastrointestinal tolerability of celecoxib, a COX-2 Specific Inhibitor, compared to naproxen and placebo. J Rheum. 2000;27: 1876–1883.

    PubMed  CAS  Google Scholar 

  53. Swan S, Rudy D, Lasseter K, et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial. Ann Intern Med. 2000;133:1–9.

    PubMed  CAS  Google Scholar 

  54. Catella-Lawson F, Mcadam B, Morrison B, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther. 1999;289:735–741.

    PubMed  CAS  Google Scholar 

  55. Daniels B, Gertz B, Morrison B, Seidenberg B. Renal safety profile of rofecoxib, a specific inhibitor of COX-2, in controlled clinical trials. Arthritis Rheum. 1999;42:S143.

    Google Scholar 

  56. Whelton A, Schulman G, Wallemark C et al. Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med. 2000;160:1465–70.

    Article  PubMed  CAS  Google Scholar 

  57. Francis KL, Chan MD, Lawrence CT, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002; 347:2104–2110.

    Article  Google Scholar 

  58. Truitt KE, Sperling RS, Ettinger WH, et al. A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis. Aging (Milano). 2001;13: 112–121.

    CAS  Google Scholar 

  59. McAdam B, Catella-Lawson F, Mardini, I, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX-2): The human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci 1999;96:272–277.

    Article  PubMed  CAS  Google Scholar 

  60. Abramowicz M. Rofecoxib for osteoarthritis and pain. The Medical Letter. 1999;41:59–61.

    Google Scholar 

  61. Leese PT, Talwalker S, Kent JD, et al. Valdecoxib does not impair platelet function. Am J Emerg Med. 2002;20:275–81.

    Article  PubMed  Google Scholar 

  62. Mukherjee D, Nissen SE, Topol EJ: Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286:954–959.

    Article  PubMed  CAS  Google Scholar 

  63. Ray WA, Stein CM, Daugherty JR, et al. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet. 2002;360:1071–1073.

    Article  PubMed  CAS  Google Scholar 

  64. Reicin AS, Shapiro D Sperling RS, et al. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). Am J Cardiol. 2002;89:204–209.

    Article  PubMed  CAS  Google Scholar 

  65. Konstam MA, Weir MR, Reicin A, et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation. 2001;104:2280–2288.

    PubMed  CAS  Google Scholar 

  66. Karim A, Tolbert D, Piergies A, et al. Celecoxib does not significantly alter the pharmacokinetics or hypoprothrombinemic effect of warfarin in healthy subjects. J Clin Pharmacol. 2000;40:655–663.

    Article  PubMed  CAS  Google Scholar 

  67. Mersfelder T, Stewart L. Warfarin and celecoxib interaction. Ann Pharmacother. 2000;34:325–326.

    Article  PubMed  CAS  Google Scholar 

  68. Juliano D. Physician Information Regarding rofecoxib. Merck & Co. Inc.; 2000.

  69. Truitt K, Ettinger W, Schnitzer T, et al. Rofecoxib, a COX-2 specific inhibitor, had clinical efficacy and overall safety in treating osteoarthritis patients aged 80 years and older. 14 th Europ League Against Rheum Congr. 1999;1:859.

    Google Scholar 

  70. American College of Rheumatology subcommittee on osteoarthritis guidelines: Recommendations for the medical managemental of osteoarthritis of the hip and knee. Arthritis Rheum. 2000;43:1905–1915.

    Google Scholar 

  71. Bradley J, Brandt K, Katz B, et al. Comparison of an anti-inflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med. 1991;325:87–91.

    Article  PubMed  CAS  Google Scholar 

  72. Williams H, Ward J, Egger J, et al. Comparison of naproxen and acetaminophen in a two-year study of treatment of osteoarthritis of the knee. Arthritis Rheum. 1993;36:1196–1206.

    Article  PubMed  CAS  Google Scholar 

  73. Discusion I: Clinical value of nonsteroidal anti-inflammatory drugs. Am J Med. 1998;104:21S-22S.

    Article  Google Scholar 

  74. Altman R. The syndrome of osteoarthritis. J Rheumatol. 1997;24:766–767.

    PubMed  CAS  Google Scholar 

  75. Bird H. When are NSAIDs appropriate in osteoarthritis? Drugs Aging. 1998;12:87–95.

    Article  PubMed  CAS  Google Scholar 

  76. Boegard T, Rudling O, Dahlstrom J, et al. Bone scintigraphy in chronic knee pain: Comparison with magnetic resonance imaging. Ann Rheum Dis. 1999;58:20–26.

    Article  PubMed  CAS  Google Scholar 

  77. Doherty M. Synovial inflammation and osteoarthritis progression: Effects of nonsteroidal antiinflammatory drugs. Osteoarthritis Cartilage. 1999;7:319–320.

    Article  PubMed  CAS  Google Scholar 

  78. Nakamura H, Yoshino S, Kato T, et al. T-cell mediated inflammatory pathway in osteoarthritis. Osteoarthritis Cartilage. 1999;7:401–402.

    Article  PubMed  CAS  Google Scholar 

  79. Walker J, Sheather-Reid R, Carmody J, et al. Nonsteroidal anti-inflammatory drugs in rheumatoid arthritis and osteoarthritis. Arthritis Rheum. 1997;40:1944–1954.

    Article  PubMed  CAS  Google Scholar 

  80. Wolfe, F, Zhao S, Lane N. Preference for nonsteroidal anti-inflammatory drugs over acetaminophen by rheumatic disease patients. Arthritis Rheum. 2000;43:378–385.

    Article  PubMed  CAS  Google Scholar 

  81. Pincus T, Koch GG, Sokka T, et al. A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee. Arthritis Rheum. 2001;44:1587–1598.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Divisions of Rheumatology and Geriatrics, University of Utah, Salt Lake City, Utah

    Sara Jane Andersen MD (GRECC Investigator, Associate Professor of Medicine)

  2. VA Salt Lake City Health Care System, 500 Foothill Blvd., 84148, Salt Lake City, Utah, USA

    Sara Jane Andersen MD (GRECC Investigator, Associate Professor of Medicine)

Authors
  1. Sara Jane Andersen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

The author has stated that she does not have a significant financial interest or other relationship with any product manufacturer or provider of services discussed in this article. The author also does not discuss the use of off-label products, which includes unlabeled, unapproved, or investigative products or devices.

About this article

Cite this article

Andersen, S.J. Cyclooxygenase-2 inhibitor treatment of older osteoarthritis patients. Compr Ther 29, 215–223 (2003). https://doi.org/10.1007/s12019-003-0025-4

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12019-003-0025-4

Keywords

Search

Navigation